title: [Outcome of patients treated with intra-peritoneal immunochemotherapy for ovarian cancer].
abstract: OBJECTIVE
  The aim of this study is to show that i.p. chemotherapy improves the evolution of the patients with an ovarian cancer, as the risk of a small number of complications due to this route of administration.
  
  
  METHODS
  85 patients (11 stage Ic, 4 IIc and 70 stage III) were treated from 1980 to 1993 (median of follow up > 77 months) by a cisplatin based immunochemotherapy administered intraperitoneally, by a needle.
  
  
  RESULTS
  Median overall survival exceeds, 72 months (60 months for stage III). Out of 41 relapses, 11 took place after 48 months of follow up. Delayed general complications consisted of 2 chronic nephotoxicities due to CDDP and one leukemia. Local complications are dominated by serous adherences (5 cases of plastic peritonitis). Secondary cytoreductions turned out to be beneficial in this series in spite of relapse diagnosis of them being carried out to late.
  
  
  CONCLUSIONS
  Classic imagery remains disappointing for the exploration of the pelvic abdominal region. Paclitaxel by i.p. way seems very promising, which should launch once again interest in secondary debulking surgery.
authors.affiliation: Service de Gynécologie, Groupe Hospitalier Bichat-Claude Bernard, Paris.
authors.forename: B
authors.initials: B
authors.lastname: Zylberberg
authors.forename: D
authors.initials: D
authors.lastname: Dormont
authors.forename: S
authors.initials: S
authors.lastname: Zylberberg
authors.forename: J
authors.initials: J
authors.lastname: Salat-Baroux
authors.forename: P
authors.initials: P
authors.lastname: Madelenat
authors.forename: J H
authors.initials: JH
authors.lastname: Ravina
authors.forename: S
authors.initials: S
authors.lastname: Zan
authors.forename: E
authors.initials: E
authors.lastname: Daraï
authors.forename: J M
authors.initials: JM
authors.lastname: Antoine
authors.forename: F
authors.initials: F
authors.lastname: Panel
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012086:Reoperation; D016019:Survival Analysis; D016896:Treatment Outcome; D014734:Vibrio cholerae / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D002945:Cisplatin
vernacular_title: Devenir des patientes traitées pour un cancer de l'ovaire par immunochimiothérapie intra-péritonéale.